Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{157971,
        author = {Anshita.N.Pande and Dr.Vivek.Paithankar},
        title = {Review on : A Systemic Review on Preclinical Experimental Studies},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {9},
        number = {8},
        pages = {348-355},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=157971},
        abstract = {Preclinical studies using animals to study the potential of a therapeutic drug or strategy are important steps before translation to clinical trials. However, evidence has shown that poor quality in the design and conduct of these studies has not only impeded clinical translation but also led to significant waste of valuable research resources. It is clear that experimental biases are related to the poor quality seen with preclinical studies. In this chapter, we will focus on hypothesis testing type of preclinical studies and explain general concepts and principles in relation to the design of in vivo experiments, provide definitions of experimental biases and how to avoid them, and discuss major sources contributing to experimental biases and how to mitigate these sources. We will also explore the differences between confirmatory and exploratory studies, and discuss available guidelines on preclinical studies and how to use them. Preclinical testing is the link between drug discovery and availability to the patient. It takes at least 12–15 years for a drug to get from the lab to clinical use.},
        keywords = {experimental bias, invivo studies, Preclinical studies },
        month = {},
        }